[go: up one dir, main page]

WO2002081747A1 - Procede de test de sensibilite aux steroides - Google Patents

Procede de test de sensibilite aux steroides Download PDF

Info

Publication number
WO2002081747A1
WO2002081747A1 PCT/JP2002/001917 JP0201917W WO02081747A1 WO 2002081747 A1 WO2002081747 A1 WO 2002081747A1 JP 0201917 W JP0201917 W JP 0201917W WO 02081747 A1 WO02081747 A1 WO 02081747A1
Authority
WO
WIPO (PCT)
Prior art keywords
steroid
examining
genes
responsiveness
steroid responsiveness
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2002/001917
Other languages
English (en)
French (fr)
Inventor
Yuji Sugita
Masayuki Heishi
Shinji Kagaya
Shigemichi Gunji
Gozoh Tsujimoto
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genox Research Inc
National Center for Child Health and Development
Original Assignee
Genox Research Inc
National Center for Child Health and Development
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genox Research Inc, National Center for Child Health and Development filed Critical Genox Research Inc
Priority to US10/474,079 priority Critical patent/US20040197786A1/en
Publication of WO2002081747A1 publication Critical patent/WO2002081747A1/ja
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503Immunoglobulin superfamily
    • C07K14/70539MHC-molecules, e.g. HLA-molecules
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00Genetically modified animals
    • A01K2217/05Animals comprising random inserted nucleic acids (transgenic)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/106Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70539MHC-molecules, e.g. HLA-molecules

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
PCT/JP2002/001917 2001-04-05 2002-03-01 Procede de test de sensibilite aux steroides Ceased WO2002081747A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US10/474,079 US20040197786A1 (en) 2001-04-05 2002-03-01 Method of examining steroid resnponsiveness

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2001-107557 2001-04-05
JP2001107557A JP2002300883A (ja) 2001-04-05 2001-04-05 ステロイド応答性の検査方法

Publications (1)

Publication Number Publication Date
WO2002081747A1 true WO2002081747A1 (fr) 2002-10-17

Family

ID=18959862

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2002/001917 Ceased WO2002081747A1 (fr) 2001-04-05 2002-03-01 Procede de test de sensibilite aux steroides

Country Status (3)

Country Link
US (1) US20040197786A1 (ja)
JP (1) JP2002300883A (ja)
WO (1) WO2002081747A1 (ja)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004076666A1 (ja) * 2003-02-28 2004-09-10 Toshihiko Shiroishi ガスダーミンファミリー

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6905827B2 (en) 2001-06-08 2005-06-14 Expression Diagnostics, Inc. Methods and compositions for diagnosing or monitoring auto immune and chronic inflammatory diseases
AU2007309726A1 (en) * 2006-04-07 2008-05-02 Xdx, Inc. Steroid responsive nucleic acid expression and prediction of disease activity
WO2008021431A2 (en) 2006-08-14 2008-02-21 Xdx, Inc. Methods and compositions for diagnosing and monitoring the status of transplant rejection and immune disorders
US8148067B2 (en) 2006-11-09 2012-04-03 Xdx, Inc. Methods for diagnosing and monitoring the status of systemic lupus erythematosus
JP2009092508A (ja) * 2007-10-09 2009-04-30 Norihiro Nishimoto リウマチ治療剤の効果の予測方法
EP2220489B1 (en) * 2007-12-14 2015-02-18 Index Pharmaceuticals AB Method for predicting re-sensitization to steroid therapy

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5985547A (en) * 1994-03-04 1999-11-16 Children's Hospital Of Philadelphia Detection of a mutation in the HLA-DMβ gene in an immunocompromised patient
US6607879B1 (en) * 1998-02-09 2003-08-19 Incyte Corporation Compositions for the detection of blood cell and immunological response gene expression
US20010034023A1 (en) * 1999-04-26 2001-10-25 Stanton Vincent P. Gene sequence variations with utility in determining the treatment of disease, in genes relating to drug processing
US20030154032A1 (en) * 2000-12-15 2003-08-14 Pittman Debra D. Methods and compositions for diagnosing and treating rheumatoid arthritis
US6905827B2 (en) * 2001-06-08 2005-06-14 Expression Diagnostics, Inc. Methods and compositions for diagnosing or monitoring auto immune and chronic inflammatory diseases

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
KELLY A.P. ET AL.: "A new human HLA class II-related locus, DM", NATURE, vol. 353, no. 6344, 10 October 1991 (1991-10-10), pages 571 - 573, XP002952631 *
POPOVICI R.M. ET AL.: "Discovery of new inducible genes in in vitro decidualized human endometrial stromal cells using microarray technology", ENDOCRINOLOGY, vol. 141, no. 9, 2000, pages 3510 - 3513, XP002952633 *
SHAMAN J. ET AL.: "Analysis of HLA-DMB mutants and -DMB genomic structure", IMMUNOGENETICS, vol. 41, 1995, pages 117 - 124, XP002952632 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004076666A1 (ja) * 2003-02-28 2004-09-10 Toshihiko Shiroishi ガスダーミンファミリー

Also Published As

Publication number Publication date
US20040197786A1 (en) 2004-10-07
JP2002300883A (ja) 2002-10-15

Similar Documents

Publication Publication Date Title
Bry et al. A model of host-microbial interactions in an open mammalian ecosystem
EP2343083A3 (en) Method of selecting patients suitable for WT1 vaccine
WO1997012992A3 (en) Diagnosis method for a disease caused by a frameshift mutation in a gene and reagents therefore
CA2465800A1 (en) Instrument
WO2005029067A3 (en) Method of diagnosing breast cancer
WO2001057274A8 (en) Human genome-derived single exon nucleic acid probes useful for analysis of gene expression in human heart
AU2003281336A1 (en) Compositions and methods for the detection of human t cell receptor variable family gene expression
AU5479599A (en) Methods and systems for sequencing dna by distinguishing the decay times of fluorescent probes
EP1721992A3 (en) Methods and nucleic acids for analyses of cellular proliferative disorders
WO2002048310A3 (en) Methods and compositions for diagnosing and treating rheumatoid arthritis
WO2002040634A3 (en) Expression miniarrays and uses thereof
IL147349A0 (en) Systems and methods for characterizing a biological condition or agent using calibrated gene expression profiles
WO2002081747A1 (fr) Procede de test de sensibilite aux steroides
EP2339348A3 (en) Method for diagnosing neuro-degenerative disease
EP3792362A8 (en) Method and kit for identifying state of colorectal cancer
WO2006021519A3 (en) Integrated device for diagnostic analyses, and relative method
MXPA01011182A (es) Metodos, composiciones y conjuntos para indicador biologico de esterilizacion.
CA2531451A1 (en) Methods and nucleic acids for analyses of colorectal cell proliferative disorders
BRPI0001536B8 (ja)
WO2002071064A1 (en) Method of examining steroid-responsiveness
CA2406443A1 (en) Method for quantification of akt protein expression
WO2007015113A3 (en) New protein isoforms of the pif-family and uses thereof
WO2004009843A3 (de) Nachweis von mikroorganismen
WO2001049879A3 (en) Methods for comparing gene expression levels or patterns in normal or tumor cells
WO2005005957A3 (en) Method of detecting cancer using delta-catenin

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): CA KR US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 10474079

Country of ref document: US

122 Ep: pct application non-entry in european phase